Nonetheless, the results from immunofluorescence imaging align with other phenotypic observations related to PD, including Th neuronal loss, microglial activation, and motor behavioral deficits, particularly in male LRRK2 G2019S carriers treated with DSS. This evidence concerns the gene LRRK2 and Parkinson disease.